未登录 分享 收藏
分享 收藏
分享 收藏
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin 接受恩沃利单抗 vedotin 治疗的患者中，药物相关皮肤不良事件与生存结局的关联。 Belkaid, Samy; Ribereau-Gayon, Emmanuel; Chabaud, Sylvie; Anriot, Julien; Chalas, Thibald; Flechon, Aude; Boyle, Helen; Vinceneux, Armelle; Berard, Frederic; You, Benoit; Freyer, Gilles; Darnis, Sophie; Tartas, Sophie; Amini-Adle, Mona 分享 收藏
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial 奥拉帕利联合间质环磷酰胺和二甲双胍治疗复发性晚期/转移性子宫内膜癌的女性：ENDOLA I/II期试验 Piffoux, Max; Leary, Alexandra; Follana, Philippe; Abdeddaim, Cyril; Joly, Florence; Bin, Sylvie; Bonjour, Maxime; Boulai, Anais; Callens, Celine; Villeneuve, Laurent; Alexandre, Marine; Schwiertz, Verane; Freyer, Gilles; Rodrigues, Manuel 分享 收藏
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2-advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2,-3, and-7 trials 在随机MONALEESA-2、-3和-7试验中，接受Ribociclib联合内分泌治疗的HR+/HER2-晚期乳腺癌患者，其疗效、安全性及患者报告结局在年轻至老年年龄组间的情况。 Hart, Lowell L.; Im, Seock-Ah; Tolaney, Sara M.; Campone, Mario; Pluard, Timothy; Sousa, Berta; Freyer, Gilles; Decker, Thomas; Kalinsky, Kevin; Sopher, Gary; Gao, Melissa; Hu, Huilin; Kuemmel, Sherko 分享 收藏
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial 新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果 Monk, B. J.; Barretina-Ginesta, M. P.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; Mccormicky, C. C.; Lorusso, D.; Moore, R. G.; Freyer, G.; O'Cearbhaill, R. E.; Heitz, F.; O'Malley, D. M.; Redondo, A.; Shahin, M. S.; Vulsteke, C.; Bradley, W. H.; Haslund, C. A.; Chase, D. M.; Pisano, C.; Holman, L. L.; Perez, M. J. Rubio; Disilvestro, P.; Gaba, L.; Herzog, T. J.; Bruchim, I.; Compton, N.; Shtessel, L.; Malinowska, I. A.; Gonzalez-Martin, A. 分享 收藏
Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012 新诊断的晚期卵巢癌(aOC)患者(pts)接受尼拉帕利(nir)一线(1L)维持治疗后的最终总生存期(OS)结果：来自PRIMA/ENGOT-OV26/GOG-3012研究 Gonzalez-Martin, A.; Pothuri, B.; Barretina Ginesta, M. P.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; Freyer, G.; O'Malley, D. M.; Heitz, F.; Shahin, M. S.; Bruchim, I.; Bradley, W. H.; Compton, N.; Malinowska, I.; Redondo, A.; Monk, B. J. 分享 收藏
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? Valenza, C.; Trapani, D.; Bidard, F. -c.; Gligorov, J.; Cortes, J.; Turner, N.; Dalenc, F.; Penault-Llorca, F.; Freyer, G.; Arnedos, M.; Villanueva, C.; Loibl, S.; Pistilli, B.; Curigliano, G. 分享 收藏
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group (vol 15, 1985 , 2024) Freyer, Gilles; Floquet, Anne; Tredan, Olivier; Carrot, Aurore; Langlois-Jacques, Carole; Lopez, Jonathan; Selle, Frederic; Abdeddaim, Cyril; Leary, Alexandra; Dubot-Poitelon, Coraline; Fabbro, Michel; Gladieff, Laurence; Lamuraglia, Michele 分享 收藏
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study Freyer, Gilles; Martinez-Janez, Noelia; Kukielka-Budny, Bozena; Ulanska, Malgorzata; Bourgeois, Hugues; Munoz, Montserrat; Morales, Serafin; Calero, Juan Bayo; Cortesi, Laura; Pinter, Tamas; Palacova, Marketa; Cherciu, Nelli; Petru, Edgar; Ettl, Johannes; de Almeida, Cecilia; Villanova, Gustavo; Raymond, Romain; Minh, Christine Ta Thanh; Rodrigues, Ana; Cazzaniga, Marina E. 分享 收藏
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary 随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果-简明语言总结 Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J. 分享 收藏
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group Freyer, Gilles; Floquet, Anne; Tredan, Olivier; Carrot, Aurore; Langlois-Jacques, Carole; Lopez, Jonathan; Selle, Frederic; Abdeddaim, Cyril; Leary, Alexandra; Dubot-Poitelon, Coraline; Fabbro, Michel; Gladieff, Laurence; Lamuraglia, Michele 分享 收藏
分享 收藏
分享 收藏
分享 收藏
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer 随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果 Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J. 分享 收藏
分享 收藏
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10 Colomban, Olivier; Swisher, Elizabeth M.; Kristeleit, Rebecca; McNeish, Iain; Shapira-Frommer, Ronnie; Goble, Sandra; Lin, Kevin K.; Maloney, Lara; Freyer, Gilles; You, Benoit 分享 收藏
Tolerance and preliminary efficacy of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with advanced ovarian carcinoma: A phase I study with expansion cohort (ICONIC) Corbaux, P.; You, B.; Kepenekian, V.; Bakrin, N.; Gelot, A.; Dayde, D.; Sajous, C.; Lamuraglia, M.; Peron, J.; Glehen, O.; Freyer, G. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
分享.png){kind=icon}
收藏.png)
ANNALS OF ONCOLOGY
OAAI